References
- Kintscher U. The burden of hypertension. EuroIntervention 2013;9(Suppl R):R12-15
- Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2013 update – a report from the American Heart Association. Circulation 2013;127:143-52
- Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23:2101-7
- Bailey J, Wan J, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010;25:495-503
- Vawter L, Tong X, Gemilyan M, Yoon, PW. Barriers to antihypertensive medication adherence among adults – United States, 2005. J Clin Hypertens (Greenwich) 2008;10:922-9
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219
- Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
- Brixner D, Jackson K, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-607
- Gupta A, Arshad S, Poulter N. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010;55:399-407
- Yang W, Chang J, Kahler K, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010;26:2065-76
- Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
- Pitsavos C, Panagiotakos DB, Chrysohoou C, Stefanadis C. Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health 2003;3:32
- ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008;17:200-8
- Teichman BJ, Burker EJ, Weiner M, Egan TM. Factors associated with adherence to treatment regimens after lung transplantation. Prog Transplant 2000;10:113-21
- Evangelista LS, Berg J, Dracup K. Relationship between psychosocial variables and compliance in patients with heart failure. Heart Lung 2001;30:294-301
- Nieuwenhuis MM, Jaarsma T, van Veldhuisen DJ, van der Wal MH. Self-reported versus ‘true’ adherence in heart failure patients: a study using the Medication Event Monitoring System. Neth Heart J 2012;20:313-19
- Nieuwenhuis MM, Jaarsma T, van Veldhuisen DJ, et al. Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J 2010;31:1486-93
- Van der Wal MH, Jaarsma T, Moser DK, et al. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J 2006;27:434-40
- Fung V, Huang J, Brand R, et al. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972-84
- Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-42
- Nagy V, Lantos E, Habony N. A study investigating the antihypertensive effect of the fixed combination of perindopril-amlodipine – the PEARL study [in Hungarian]. Lege Artis Medicinae 2010;20:499-507
- Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 2015;13;116:1058-73
- Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
- Heidenreich PA, Fonarow GC. Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. Am Heart J 2006;152:935-9
- Granger CB, Gersh BJ. Clinical trials and registries in cardiovascular disease: competitive or complementary? Eur Heart J 2010;31:520-1